Vincristine Teva 1 mg/1 ml 1ml
Vincristine 1 mg/1 ml is used to treat various types of cancer. It is a cancer chemotherapy drug that is usually used with other chemotherapy drugs to slow or stop cancer cell growth.
- Additional information
- Doses and Uses
- Shipping & Payment
- Reviews (0)
Buy online Vincristine Sulfate 1 mg/ml solution for injection.
Each 1 ml contains 1.0 mg of vincristine sulfate.
Excipient with known effect: benzyl alcohol (9 mg per ml).
Vincristine is used to treat various types of cancer. It is a cancer chemotherapy drug that is usually used with other chemotherapy drugs to slow or stop cancer cell growth.
Vincristine sulfate injection (vincristine sulfate) is indicated in acute leukemia.
Vincristine sulfate injection (vincristine sulfate) has also been shown to be useful in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.
Vincristine sulfate is used either alone or in conjunction with other oncolytic drugs for the treatment of:
Intrathecal administration of Vincristine sulfate is usually fatal.
Hypersensitivity to Vincristine sulfate or to any of the excipients.
Patients with the demyelinating form of Charcot-Marie-Tooth syndrome should not be given Vincristine.
As Vincristine Sulfate solution for injection contains benzyl alcohol it must not be given to premature babies or neonates.
Side effects following the use of Vincristine are dose related. In children under 13 years of age, death has occurred following doses of Vincristine that were 10 times those recommended for therapy. Severe symptoms may occur in this patient group following dosages of 3 to 4 mg/m2. Adults can be expected to experience severe symptoms after single doses of 3 mg/m2 or more. Therefore, following administration of doses higher than those recommended patients can be expected to experience side-effects in an exaggerated fashion.
Nausea, vomiting, weight loss, diarrhea, mouth sores, dizziness, or headache may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
This medication can also cause constipation, which in some cases may become serious. Consult your doctor or pharmacist about how you can prevent constipation (such as eating a diet high in fiber, drinking plenty of water). Ask about regularly using a stool softener such as docusate, avoiding bulk-forming laxatives, and choosing a stimulant laxative. Tell your doctor or pharmacist promptly if you develop constipation, stomach/abdominal pain, or bloating.
Temporary hair loss may occur. Normal hair growth should return after treatment has ended.
People using this medication may have serious side effects. However, your doctor has prescribed this drug because he or she has judged that the benefit to you is greater than the risk ofside effects. Careful monitoring by your doctor may decrease your risk.
This medication may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor right away if you have any signs of infection (such as fever, chills, persistent sore throat, cough).
This medication commonly affects the nerves and muscles in your body. Most of these side effects go away after this medication is stopped, however some effects may persist for a long time. Tell your doctor right away if you have any of the following: painful/difficult urination, decreased urination, pain (including in the joints, back, muscles), numbness/tingling/burning/pain of the feet/hands, weakness, difficulty walking, loss of coordination/balance, inability to move your muscles (including the muscles of your face and other parts of your body), drooping eyelids, hoarseness, trouble speaking.
Tell your doctor right away if you have any serious side effects, including: vision/hearing changes, mental/mood changes (such as depression, hallucinations, confusion), easy bleeding/bruising, severe tiredness.
Get medical help right away if you have any very serious side effects, including: seizures, chest/jaw/left arm pain, signs of liver problems (such as dark urine, persistent nausea, vomiting, stomach/abdominal pain, yellowing eyes/skin).
Trouble breathing may rarely occur with Vincristine treatment, especially when it is given with another chemotherapy drug, mitomycin-C. Patients with lung problems may be more sensitive to this side effect. Long-term treatment of this side effect may be required if it worsens. This effect may occur within minutes to several hours after Vincristine is given and up to 2 weeks after the dose of mitomycin-C. Get medical help right away if you have shortness of breath or coughing. If you have this reaction, you should not receive Vincristine again.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
Solution for injection.
A sterile, colourless solution.
Store Vincristine in a refrigerator (2°C – 8 °C). Keep the vial in the outer carton, in order to protect from light.
|Forms of release|| |
Solutions for injections
|Volume / Weight|| |
|Country/Region of Manufacture|| |
|Expiration date|| |
This preparation is for intravenous use only.
Neurotoxicity appears to be dose related. Extreme care must be used in calculating and administering the dose of Vincristine Sulfate Injection, USP (vincristine sulfate) since overdosage may have a very serious or fatal outcome.
Special Dispensing Information: WHEN DISPENSING VINCRISTINE SULFATE INJECTION (vincristine sulfate) , USP IN OTHER THAN THE ORIGINAL CONTAINER, IT IS IMPERATIVE THAT IT BE PACKAGED IN THE PROVIDED OVERWRAP WHICH BEARS THE FOLLOWING STATEMENT: “DO NOT REMOVE COVERING UNTIL MOMENT OF INJECTION. FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY” (see WARNINGS). A syringe containing a specific dose must be labeled, using the auxiliary sticker provided, to state: “FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY.”
The concentration of Vincristine Sulfate Injection, USP (vincristine sulfate) is 1 mg/mL. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP (vincristine sulfate) into an accurate dry syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.
Caution: It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissue during intravenous administration of Vincristine Sulfate Injection, USP (vincristine sulfate) may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage will help disperse the drug and may minimize discomfort and the possibility of cellulitis.
Vincristine Sulfate Injection, USP (vincristine sulfate) must be administered via an intact, free-flowing intravenous needle or catheter. Care should be taken that there is no leakage or swelling occurring during administration (see BOXED WARNINGS).
The solution may be injected either directly into a vein or into the tubing of a running intravenous infusion (see Drug Interactions below). Injection of Vincristine Sulfate Injection, USP (vincristine sulfate) should be accomplished within 1 minute.
The drug is administered intravenously at weekly intervals.
The usual dose of Vincristine Sulfate Injection, USP (vincristine sulfate) for pediatric patients is 1.5-2 mg/m². For pediatric patients weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of Vincristine Sulfate Injection, USP for adults is 1.4 mg/m². A 50% reduction in the dose of Vincristine Sulfate Injection, USP (vincristine sulfate) is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.
Vincristine Sulfate Injection, USP (vincristine sulfate) should not be given to patients while they are receiving radiation therapy through ports that include the liver. When Vincristine Sulfate Injection (vincristine sulfate) , USP is used in combination with L-asparaginase, Vincristine Sulfate Injection, USP (vincristine sulfate) should be given 12 to 24 hours before administration of the enzyme in order to minimize toxicity; administering L-asparaginase before Vincristine Sulfate Injection, USP (vincristine sulfate) may reduce hepatic clearance of Vincristine.
|STANDART SHIPPING WORLDWIDE|
|WEIGHT (kg)||COST ($US)||ESTIMATED |
|0 - 0.199||6.50||15 - 21 working days||Available|
|0.200 - 0.250||8.00||15 - 21 working days||Available|
|0.251 - 0.500||14.00||15 - 21 working days||Available|
|0.501 - 1.000||20.00||15 - 21 working days||Available|
|1.000 - 2.000||25.00||15 - 21 working days||Available|
Depending on the method of payment, additional Fees / VAT are charged.
And also there is a system of bonuses that you can spend on your next purchases.
Only logged in customers who have purchased this product may leave a review.